Cross-Platform Comparative Spatial Transcriptomics in High-Grade Serous Carcinoma

PURPOSE: High-grade serous carcinoma (HGSC) is a remarkably heterogeneous tumor. The purpose of this study was to directly compare the reproducibility of transcriptomic profiles and biologically relevant molecular features across two spatial transcriptomics platforms-GeoMx Digital Spatial Profiler (GeoMx) and Visium Spatial Gene Expression (Visium) using AI-defined tumor regions associated with clinical outcome. MATERIALS AND METHODS: A combination of artificial intelligence (AI)-identified tumor regions and Visium Spatial Gene Expression (Visium) was previously applied to formalin-fixed, paraffin-embedded (FFPE) HGSC samples to identify molecular features associated with disease outcome. Here, we apply GeoMx Digital Spatial Profiler (GeoMx) to the same FFPE cohort (n = 16) to directly compare transcriptional profiles between platforms. We analyzed AI-identified regions, including high-confidence (HC) and lower-confidence "background tumor" (BG) areas from the same tumor. RESULTS: ), and pathway enrichment patterns, including TNF-alpha signaling and p53 pathways, were similar. Outcome-related genes of interest (GOIs) exhibited distinct expression patterns between HC and BG regions: JUN, ITGB8, KRT7, and TACSTD2 were enriched in short progression-free interval (PFI-S), whereas PPIB, GSTP1, and LPAR3 were associated with long progression-free interval (PFI-L). Additionally, RNA in situ hybridization (RNA-ISH) validated GeoMx-identified HC region-specific markers. Higher NR1D2 and TREX1 expression in PFI-S tumors and elevated H1-5 and HMGB3 expression in PFI-L tumors were detected, consistent with the differential expression trends observed in GeoMx. CONCLUSIONS: Together, our results demonstrate that key transcriptomic features of HGSC are consistently captured across ST technologies, supporting their translational utility. The ability to accurately replicate transcriptomic profiles across two different platforms expands translational applications and enhances the identification of biologically significant molecular features relevant to HGSC outcomes.